Companies › Enliven Therapeutics
2 active drug programs in 4 registered trials: 4 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ELVN-002 HER2 kinase inhibitor | ERBB2 | Phase 1 | HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Breast Cancer | Jan 2027 |
| ELVN-001 Third-generation BCR-ABL tyrosine kinase inhibitor effective against T315I mutation | BCR, ABL1 | Phase 1 | Chronic Myeloid Leukemia; CML (Chronic Myelogenous Leukemia) | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05650879 | ELVN-002 | Phase 1 | HER2 Mutant Non-small Cell Lung Cancer | Oncology | Jul 2026 |
| NCT06328738 | ELVN-002 | Phase 1 | HER2-positive Breast Cancer | Oncology | Jan 2027 |
| NCT05304377 | ELVN-001 | Phase 1 | Chronic Myeloid Leukemia | Oncology | Dec 2027 |
| NCT06787144 | ELVN-001 | Phase 1 | CML (Chronic Myelogenous Leukemia) | Oncology | Jan 2028 |
Cash and short-term investments of $884m on 2026-09-30; operating cash outflow about $68m a year; runway about 157 months at that burn, to Oct 2039
Press releases filed as 8-K in the last year:
Held by 14 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.